Skylar Jeremias

Cancer survivors face lasting skin, hair, and nail reactions; dermatology follow-up and treatments can restore appearance, improve quality of life, and monitor risks.

Meta-analysis finds alopecia areata links to lower melanoma odds and no added skin cancer risk despite ultraviolet-exposed scalp, informing Janus kinase inhibitor safety.

Study finds endometriosis severity plateaus after 30, but surgery risk and complexity climb in older women as fibrosis and adhesions build.

Phenotype-based care improves childhood obesity diagnosis and treatment, including obesity types, hypothalamic obesity, drugs, and surgery.

The scoping review shows menopause and multiple sclerosis (MS) shift from fewer relapses to higher symptom burden, highlighting care gaps for older women with MS.

Phase 3 THRIVE-AA2 data show deuruxolitinib in alopecia areata boosts hair regrowth and satisfaction in severe AA, with manageable safety, vs placebo.

Data from the STEPIn trial shows early intervention for plaque psoriasis with secukinumab delivers durable disease control, with some staying clear up to a year post treatment.

Psoriasis and macrophage research spotlights M1/M2 imbalance, interleukin therapies, and single-cell insights pointing to new precision targets.

New evidence links alopecia areata and atopic dermatitis overlap, revealing eczema-like immune signatures and dual-use JAK/OX40 therapies to watch.

Photodynamic therapy expands from actinic keratosis to acne, infections, and rejuvenation—while experts urge clearer, mechanism-based guidelines.

Global pediatric HIV data show dolutegravir links to early modest weight gain that plateaus by year 2, easing concerns and highlighting regional nutrition gaps.

A global cohort has tracked pediatric HIV growth after dolutegravir, showing early catch-up weight gain, then stable BMI without long-term obesity risk.

A federal court blocked RFK Jr's vaccine agenda, freezing the ACIP shakeup and safeguarding child vaccine access as the legal fight over vaccines intensifies.

Study links PFAS and forever chemicals in children and teens to lower bone density in adolescents—especially girls—highlighting critical exposure windows.

Peter Staley at CROI 2026 on defending 45 years of HIV progress: how clinicians, payers, and advocates can resist—quietly or publicly—and why it matters.

Elona Toska, MSc, DPhil, explores drivers of HIV in pregnant women and young mothers: biology, relationships, and postpartum treatment drop-off.

From innovative therapies to global care strategies, HIV experts at CROI 2026 share the breakthroughs and lessons they hope every viewer, near or far, takes home.

Wildfire smoke from the Canadian wildfires in 2023 was linked to a higher incidence of severe strokes and increased hemorrhagic risk, according to new study findings.

Phase 3 data show povorcitinib delivers rapid lesion clearance in HS, improves quality of life outcomes, and offers favorable safety through 24 weeks.

Elona Toska, MSc, DPhil, explores drivers of HIV in pregnant women and young mothers: biology, relationships, and postpartum treatment drop-off.

Sweeping federal funding cuts and stalled prevention efforts are unraveling hard-won gains in HIV research and access, warns Peter Staley.

Todd Brown, MD, PhD, explains key considerations for using GLP‑1 drugs in patients with HIV, including titration tips, surgery precautions, and bone/muscle monitoring.

At CROI 2026, experts warned that missing HBV screening risks reactivation during HIV therapy switches.

The REPRIEVE study finds statins cut heart events in HIV by lowering lipids, inflammation, and hypertension risk.

Victor Appay, PhD, explains how long-term ART slows immune aging, boosting HIV viral suppression and paving the way for remission without therapy.

Doxy-PEP reshapes STI prevention, while congenital syphilis surges; experts urge scaling HIV and STI care infrastructure to improve testing and treatment access.

CROI 2026 highlights will include HIV prevention, long-acting treatments, and other advancements shaping research, clinical practice, and global policy.

City leaders share real-world GLP-1 coverage tactics, showing how public employers balance access, costs, and lasting weight-management outcomes with data-driven oversight.

The FDA granted sibeprenlimab accelerated approval for nephropathy after data showed it cut IgA nephropathy proteinuria by about 50% via APRIL inhibition.